Will Wang

Will Wang is a counsel in the firm’s Business Law department and a member of its Life Sciences group. Will has extensive experience in capital markets transactions, public mergers and acquisitions, privatizations, SEC compliance and other general corporate matters. His transactional work spans several industries, including life sciences, technology, healthcare, education and financial services. Will also represents private equity firms and portfolio companies in early and late stage venture capital and growth equity investments.

Prior to joining Goodwin in 2018, Will was an associate at Skadden, Arps, Slate, Meagher & Flom LLP. He speaks English and Mandarin.

Will's key experience includes representation of:

Capital Markets:

• BeiGene Inc. (NASDAQ: BGNE) in its US$3.5 billion initial public offering on the STAR Board of Shanghai Stock Exchange
• Underwriters in Centogene N.V. (NASDAQ: CNTG)’s US$28 million follow-on offering
• Huya Inc. (NYSE: HUYA) in its US$180 million initial public offering and listing on the New York Stock Exchange*
• PPDai Group Inc. (NYSE: PPDF) in its US$221 million initial public offering and listing on the New York Stock Exchange*
• Yirendai Ltd. (NYSE: YRD) in its US$75 million initial public offering and listing on the New York Stock Exchange*
• Perfect World Co., Ltd. (NASDAQ: PWRD) in its going-private and delisting from NASDAQ*
• China Literature Limited (HKEx: 0772) in its spin-off from Tencent Holdings Limited (China), via a HK$8.3 billion (US$1.06 billion) initial public offering and listing on the Hong Kong Stock Exchange*
• Yixin Group (HKEx: 2858) in its HK$6.8 billion (US$867 million) initial public offering and listing on the Hong Kong Stock Exchange*
• ZhongAn Online Property & Casualty Insurance (HKEx: 0672) in its US$1.5 billion initial public offering and listing on the Hong Kong Stock Exchange*
• China Education Group Holdings (HKEx: 0839) in its US$439 million initial public offering on the Hong Kong Stock Exchange*
• China YuHua Education Corporation Limited (HKEx: 6169) in its HK$1.54 billion (US$198 million) initial public offering on the Hong Kong Stock Exchange*
• Underwriters in Modern Dental Group Limited (HKEx: 3600)’s US$135 million initial public offering on the Hong Kong Stock Exchange*
• Guangdong Kanghua Healthcare Co., Ltd. (HKEx: 3689) in its HK$885 million (US$114 million) initial public offering and listing of H shares on the Hong Kong Stock Exchange*
• Underwriters in Wisdom Education International Holdings Company Limited (China) (HKEx: 6068)’s HK$850 million (US$107 million) initial public offering and listing on the Hong Kong Stock Exchange*
• New China Life Insurance Company Ltd. (HKEx: 1336) in its US$1.4 billion initial public offering on the main board of the Hong Kong Stock Exchange*
• China Everbright Bank Company Limited (HKEx: 6818) in its US$2.6 billion initial public offering on the Hong Kong Stock Exchange*

Growth Equity, PIPEs and Mergers & Acquisitions:

• eMagin (NYSE: EMAN), a leading OLED microdisplay manufacturer, in its $218 million sale to Samsung Display.
• edX, a leading online learning platform funded by Harvard and MIT, in its $800 million asset sale to 2U, Inc. (NASDAQ: TWOU)
• FastPay, an automated payment solution provider, in its $110 million asset sale to AvidXchange (NASDAQ: AVDX)
• Hillhouse Capital and affiliates in more than 20 matters. Certain publicly disclosed matters include investments in Beam Therapeutics, Bilibili, I-MAB, TAL Education, FUTU, iQiyi and Pinguoduo.
• DST Global and its affiliates in more than 10 matters
• FountainVest Partners in a number of matters. Certain publicly disclosed matters include investment in 360 DigiTech (NASDAQ: QFIN), a leading digital consume finance platform, and sale of a luxury colored gem jewelry business to one of the largest jewelry groups in Asia
• Level Equity and its affiliates in a number of matters. Certain publicly disclosed matters include its investment in Vacasa Inc. (NASDAQ: VCSA), a leading vacation rental management platform
• 9Yards Capital and its affiliates in a number of matters. Certain publicly disclosed matters include its investments in Robinhood Market (NASDAQ: HOOD) and Emerge Market, a leading platform for freight procurement
• Danone Manifesto Ventures in its investment in Splendid Spoon, a national meal delivery service platform
• Streetcred Labs, Inc. in its $34.5 million asset sale to Snap Inc. (NYSE: SNAP)
• T. Rowe Price in its $14 million PIPE in Ranger Energy Services, Inc. (NYSE: RNGR)
• Zai Lab (NASDAQ: ZLAB) in its $30 million PIPE in MacroGenics (NASDAQ: MGNX)
• HighTide Therapeutics in its $60 million Series B financing
• GreyCroft in a number of growth equity investments in Asia
• Ipreo in connection with its China joint venture with Hundsun Technologies
• IPACKCHEM Group in its acquisition of Jiangsu Rotam Boxmore Packing
• Banyan Treatment Centers, in its $254 million sale to The Rise Fund, TPG’s multi-sector global impact investing fund.
• Meilishuo Limited, a Chinese online fashion retailer, in its US$2.4 billion merger with Mogujie*
• Yidao Yongche, a Chinese car-hailing, in its US$700 million acquisition by LeTV*
• 58.com, the largest classified online marketplace, in the spin-off of its used car trading business*
• China Development Bank Capital Co., Ltd. in its public takeover of New Capital International Investment Limited*
• State Development & Investment Corporation in its acquisition of an Indonesian mining company*
• Aluminum Corporation of China in its acquisition of an Indonesian mining company*

*Denotes experience prior to joining Goodwin.